Genetik Lifesciences To Produce Affordable Aphotericin B Injection To Treat Black Fungus Infection In COVID Patients

The Wardha-based Genetik Lifesciences has received the approval from the Food and Drug Administration (FDA) to produce the Amphotericin B injection for the black fungus infection during the Covid-19 period.

The production of Amphotericin B will commence at the Wardha plant of the company in the coming fortnight.

“On the initiative of Union Minister @nitin_gadkari, Wardha's Genetic Life Sciences has received FDA approval to manufacture Amphotericin B injection for black fungus infection (Mucormycosis) occurring during the corona period. Its production will start in Wardha in 15 days,” the senior minister’s office confirmed in its official Twitter handle.

In fact, the company on Wednesday (12 May) already kicked off the manufacturing of the vital Remdesivir injection that is widely used to treat patients infected with Covid-19, The Economic Times reports.